Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis

Affiliations

• ¹ Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada; Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
• ² Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Faculty of Medicine, Toulouse University Hospital, Toulouse, France; INSERM, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426-University Paul Sabatier Toulouse, Toulouse, France.
• ³ Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
• ⁴ Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada; Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada. Electronic address: laurent.azoulay@mcgill.ca.